
Filing Meeting /STN125350/0/CSL/Pratibha - Hizentra, June 11, 2009

 

 
Rana, Pratibha


From: Stockbridge, Lisa L
Sent: Thursday, June 11, 2009 10:47 AM
To: Rana, Pratibha; Zhang, Pei; Hu, Jiang; Tanksley, Sarah; Kannan, Bhanu; Ko, Hon Sum;
 Mahmood, Iftekhar; QuanderIII, Joseph; Struble, Evi; Trout, Deborah; Virata, Maria Luisa;
 Zhong, Lilin; Frazier, Douglas; Fisher, Robert
Cc: Anderson, Jeffrey; Jain, Nisha
Subject: RE: Filing Meeting /STN125350/0/CSL/Pratibha

Pratibha,

This application is fileable from APLB's perspective.

Please let the sponsor know that "Hizentra" is acceptable at this point. (There will be a re-evaluation 90 days from BLA
 approval. The sponsor is not required to do anything more concerning the re-evaluation --- we do that here.) Also, please
 be sure to close out the milestone for the PNR.

Thanks,

LLS


From: Rana, Pratibha
Sent: Wednesday, June 10, 2009 4:22 PM
To: Zhang, Pei; Hu, Jiang; Tanksley, Sarah; Kannan, Bhanu; Ko, Hon Sum; Mahmood, Iftekhar; QuanderIII, Joseph; Stockbridge, Lisa L;
 Struble, Evi; Trout, Deborah; Virata, Maria Luisa; Zhong, Lilin; Frazier, Douglas; Fisher, Robert
Cc: Anderson, Jeffrey; Jain, Nisha
Subject: Filing Meeting /STN125350/0/CSL/Pratibha

Hello All,

Please enter a filing memo or send me an email stating this BLA is fileable.
 Sara T has already entered her memo. If all of you agree that this is fileable and if there are no issues to discuss then we
 can cancel the filing meeting. But if there are issues we want to discuss then we should definitely meet tomorrow.
 Pratibha

Pratibha Rana, M.S.
 Regulatory Project Manager

FDA/CBER/OBRR
 Division of Blood Applications
 1401 Rockville Pike
 Rockville, MD 20852
 Office: (301) 827-6124
 Fax: (301) 827-2857
 email: pratibha.rana@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY
 CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER
 LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any
 review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have
 received this document in error, please immediately notify the sender immediately by e-mail or phone."
